HomeEverythingEducation
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Veeva Summit Highlights AI's Future in Biopharma

Created at 5 Jun · 9:04 AM1 source
IN SHORT

Over 2,000 attendees gathered at the Veeva Summit to explore the future of AI in the biopharmaceutical industry. Leaders from AOP Health, Boehringer Ingelheim, GSK, Haleon, MSD, Novo Nordisk, Roche, Sanofi, and Sobi shared strategies for streamlining operations.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Key Numbers

2,000+summit attendees

Who's Involved

Veeva
host of the summit on AI in biopharma
AOP Health, Boehringer Ingelheim, GSK, Haleon, MSD, Novo Nordisk, Roche, Sanofi,
industry leaders sharing strategies at the summit

↳ Why This Matters

The summit highlights how major pharmaceutical companies are adopting AI to improve efficiency and connectivity, signaling a significant shift in industry operations and potentially accelerating drug development and market access.

Key facts

  • Veeva Summit focused on AI's role in the biopharmaceutical industry.
  • Over 2,000 people attended the event.
  • Industry leaders shared strategies for streamlining operations.
  • Companies like GSK, Sanofi, and Roche participated.

The Veeva Summit brought together over 2,000 attendees to discuss the future of artificial intelligence within the biopharmaceutical sector. Key industry players, including AOP Health, Boehringer Ingelheim, GSK, Haleon, MSD, Novo Nordisk, Roche, Sanofi, and Sobi, were present. These leaders shared their insights and strategies focused on enhancing operational efficiency and connectivity within their organizations through AI. The event underscored the growing importance of AI in transforming biopharmaceutical operations.

Frequently asked questions

The main focus was the future of artificial intelligence (AI) in the biopharmaceutical industry.

Over 2,000 people attended the event.

Companies such as AOP Health, Boehringer Ingelheim, GSK, Haleon, MSD, Novo Nordisk, Roche, Sanofi, and Sobi were represented.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence

How It Developed

5 Jun · 8:54 AM
Le Sommet Veeva a réuni plus de 2 000 personnes pour explorer l'avenir de l'IA dans l'industrie biopharmaceutique, avec des leaders partageant leurs stratégies.
PRN | All News Releases via PiQSuite

Sources

T1
Le Sommet Veeva présente Falcon et l'avenir de la biopharmacie agentiquem.piqsuite.com

Related Stories

BofA extends $520 million credit line to OpenAI ahead of IPO
8 Jul · 4:59 PM
Nvidia CEO Jensen Huang: Engineers prefer building AI agents to coding
9 Jul · 5:35 AM
OpenAI, Meta, xAI Unveil New AI Models Amid National Security Review
8 Jul · 1:10 PM
Google revamps Android AI dev benchmark, adds Fable 5 and other agents
8 Jul · 4:45 PM
OpenAI launches GPT-Live voice models for simultaneous listening and speaking
8 Jul · 5:56 PM